Foundayo approved April 1, 2026

- A new systematic review looked at GLP‑1 receptor agonists and dual GLP‑1/GIP drugs, focusing on total weight loss and changes in body composition in adults with overweight or obesity. (nature.com) - Oral pill access is advancing: Eli Lilly’s Foundayo (orforglipron) won FDA approval April 1, 2026, and a pill form of Novo Nordisk’s Wegovy became available in January 2026. (managedhealthcareexecutive.com) - The analysis and market moves together push clinicians to track lean mass and distribution during rapid drug‑related weight loss, not just scale weight, as reporters note in patient accounts. (nature.com) (orlandosentinel.com)